N@N

Debjit Chattopadhyay Maintained (VRTX) at Strong Buy with Increased Target to $286 on, Dec 1st, 2021

^{Published on 2024-10-27 18:49:39 - WOPRAI, Debjit Chattopadhyay}
 

Debjit Chattopadhyay of Guggenheim, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Increased Target from $250 to $286 on, Dec 1st, 2021.

Debjit has made no other calls on VRTX in the last 4 months.

There are 7 other peers that have a rating on VRTX. Out of the 7 peers that are also analyzing VRTX, 3 agree with Debjit's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Do Kim of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $218 on, Friday, November 19th, 2021
• Evan Seigerman of "BMO Capital" Initiated at Hold and Held Target at $202 on, Friday, November 19th, 2021
• Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $213 on, Thursday, September 9th, 2021

These are the ratings of the 4 analyists that currently disagree with Debjit

---

• Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $250 on, Wednesday, November 3rd, 2021
• Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Tuesday, November 2nd, 2021
• Brian Skorney of "Baird" Maintained at Buy and Held Target at $240 on, Tuesday, October 19th, 2021
• Matthew Harrison of "Morgan Stanley" Downgraded from Hold to Sell and Held Target at $202 on, Tuesday, September 7th, 2021

Contributing Sources

---